New immunotherapy combo targets rare cancers left behind by progress
NCT ID NCT06790706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinoma) that have progressed after at least one prior treatment. The study aims to see if the drug combo can control the cancer for at least 24 weeks. About 27 participants will be treated across 15 French centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- domvanalimab and zimberelimab (immunotherapy drugs)
- What this could lead to
- If successful, this could offer a new treatment option for several rare cancers that currently have few effective therapies after standard treatment fails.
- What could go wrong
- This is an early phase 2 trial with only 27 participants, so results may not apply broadly. The drugs may cause immune-related side effects, and the combination may not work for all cancer types studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CARCINOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HM, TIMONE Hospital, medical oncology department
Marseille, 13009, France
-
AP-HP, Tenon Hospital, medical oncology department
Paris, 75020, France
-
Centre Eugène Marquis, medical oncology department
Rennes, 35042, France
-
Centre Hospitalier Universitaire de Lille, medical oncology department
Lille, 59037, France
-
Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital
Lyon, 69003, France
-
Hospices Civils de Lyon, Medical Oncology Department, Lyon SUD Hospital
Pierre-Bénite, 69310, France
-
Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital
Bron, 69500, France
-
Insitut de Cancérologie Strasbourg Europe, medical oncology department
Strasbourg, 67200, France
-
Institut Bergonié, medical oncology department
Bordeaux, 33076, France
-
Institut Curie, thoracic oncology department
Paris, 75005, France
-
Institut Gustave Roussy, medical oncology department
Villejuif, 94805, France
-
Institut Paoli-Calmettes Marseille, medical oncology department
Marseille, 13009, France
-
Institut Régional du Cancer de Montpellier, medical oncology department
Montpellier, 34298, France
-
Institut de Cancerologie de l'Ouest , medical oncology department
Angers, 49055, France
-
ONCOPOLE Claudius Regaud, IUCT-Oncopole, medical oncology department
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- Shorter radiation after thymic tumor surgery may cut side effects
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Two-Drug combo aims to stall rare gut tumors